These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2223371)

  • 1. Muscle relaxation rates in individuals susceptible to malignant hyperthermia.
    Urwyler A; Ellis FR; Halsall PJ; Hopkins PM
    Br J Anaesth; 1990 Sep; 65(3):421-3. PubMed ID: 2223371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal relaxation rates in subjects susceptible to malignant hyperthermia.
    Lennmarken C; Rutberg H; Henriksson KG
    Acta Neurol Scand; 1987 Feb; 75(2):81-3. PubMed ID: 3577679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
    Mortier W; Breucking E
    Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies.
    Mezin P; Payen JF; Bosson JL; Brambilla E; Stieglitz P
    Br J Anaesth; 1997 Sep; 79(3):327-31. PubMed ID: 9389850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
    Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a 5HT(2) receptor agonist on anaesthetized pigs susceptible to malignant hyperthermia.
    Gerbershagen MU; Wappler F; Fiege M; Kolodzie K; Weisshorn R; Szafarczyk W; Kudlik C; Schulte Am Esch J
    Br J Anaesth; 2003 Aug; 91(2):281-4. PubMed ID: 12878630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
    Fiege M; Wappler F; Scholz J; von Richthofen V; Brinken B; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal muscle contraction characteristics in vivo in malignant hyperthermia susceptible subjects.
    Bäckman E; Lennmarken C; Rutberg H; Henriksson KG
    Acta Neurol Scand; 1988 Apr; 77(4):278-82. PubMed ID: 3389078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in ryanodine-induced contractures by stimulus frequency in malignant hyperthermia susceptible and malignant hyperthermia nonsusceptible dog skeletal muscle.
    Sudo RT; Nelson TE
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1331-6. PubMed ID: 9316843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia.
    Wappler F; Scholz J; Köchling A; Steinfath M; Krause T; Schulte am Esch J
    Br J Anaesth; 1997 May; 78(5):541-7. PubMed ID: 9175969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of vecuronium and doxapram in patients susceptible to malignant hyperthermia.
    Ording H; Fonsmark L
    Br J Anaesth; 1988 Mar; 60(4):445-9. PubMed ID: 2895665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atracurium and its antagonism by neostigmine (plus glycopyrrolate) in patients susceptible to malignant hyperthermia.
    Ording H; Nielsen VG
    Br J Anaesth; 1986 Sep; 58(9):1001-4. PubMed ID: 3092848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and muscle biopsy findings in malignant hyperthermia susceptibility.
    Ranklev E; Henriksson KG; Fletcher R; Germundsson K; Oldfors A; Kalimo H
    Acta Neurol Scand; 1986 Dec; 74(6):452-9. PubMed ID: 3825502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H; Bendixen D
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.
    Weisshorn R; Wappler F; Fiege M; Gerbershagen MU; Kolodzie K; Alberts P; Horn EP; Schulte Am Esch J
    J Clin Anesth; 2004 Aug; 16(5):353-7. PubMed ID: 15374556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ondansetron-induced muscular contractures in malignant hyperthermia-susceptible individuals.
    Johannsen S; Roewer N; Schuster F
    Anesth Analg; 2012 Oct; 115(4):925-8. PubMed ID: 22696611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In-vitro-effects of cocaine in skeletal muscle specimens of patients susceptible to malignant hyperthermia].
    Weisshorn R; Wappler F; Fiege M; Gerbershagen M; Schulte Am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Mar; 37(3):138-43. PubMed ID: 11889614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystathionine β-synthase-derived hydrogen sulfide is involved in human malignant hyperthermia.
    Vellecco V; Mancini A; Ianaro A; Calderone V; Attanasio C; Cantalupo A; Andria B; Savoia G; Panza E; Di Martino A; Cirino G; Bucci M
    Clin Sci (Lond); 2016 Jan; 130(1):35-44. PubMed ID: 26460077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The action of ketamine on muscle contractile behavior. In vitro studies on the musculature of subjects susceptible to malignant hyperthermia].
    Hackl W; Winkler M; Mauritz W; Steinbereithner K
    Anaesthesist; 1989 Dec; 38(12):681-5. PubMed ID: 2619030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Porcine malignant hyperthermia: halothane effects on force generation in skeletal muscles.
    Gallant EM; Goettl VM
    Muscle Nerve; 1989 Jan; 12(1):56-63. PubMed ID: 2747737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.